Literature DB >> 18652825

Histone deacetylase inhibitor-induced cellular apoptosis involves stanniocalcin-1 activation.

A Y S Law1, K P Lai, W C Lui, H T Wan, Chris K C Wong.   

Abstract

Our previous studies have demonstrated the involvement of HIF-1 and p53 in the regulation of stanniocalcin-1 (STC1) gene transcription in human cancer cells. In this study, we reported that the treatment of human colon adenoma HT29 cells with a histone deacetylase (HDAC) inhibitor (i.e. trichostatin A, TSA) induced both cellular apoptosis and STC1 expression. The activation of STC1 expression was also observed in other TSA-treated human cancer cells (i.e. SKOV3, CaCo-2, Jurkat and CNE-2 cells). STC1 mRNA was rapidly induced within 4 h in TSA-treated HT29 cells, and was found to be transcriptionally regulated and was independent of new protein synthesis as revealed by ActD and CHX treatment respectively. The induction was correlated with increased cellular levels of acetyl histone H3 and H4 and acetyl NFkappaB. Chromatin immunoprecipitation (ChIP) assay showed the increased binding of acetyl histone H3 and H4 to STC1 promoter in the TSA-treated cells. A cotreatment of HT29 cells with a NFkappaB inhibitor (parthenolide) significantly inhibited the TSA-induced cellular levels of acetyl NFkappaB p65 and abolished the stimulation of STC1 gene expression. ChIP assay also demonstrated that TSA treatment increased while TSA/parthenolide cotreatment decreased NFkappaB p65 binding to STC1 gene promoter. In the STC1-luciferase promoter construct (1 kb) study, the data implied that the promoter can be activated by TSA treatment. Interestingly, the promoter region contains 2 putative NFkappaB binding sites. Consistent with the STC1mRNA expression data, TSA/parthenolide cotreatment also significantly inhibited the TSA-induced STC1 promoter-driven luciferase activity. Importantly, TSA-induced apoptotic process was found to be significantly reduced by the silencing of STC1 expression. This is the first study to show that histone hyper-acetylation and the recruitment of activated NFkappaB stimulated STC1 gene expression. In addition, our results support the notion that STC1 is a pro-apoptotic factor.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18652825     DOI: 10.1016/j.yexcr.2008.07.002

Source DB:  PubMed          Journal:  Exp Cell Res        ISSN: 0014-4827            Impact factor:   3.905


  10 in total

1.  Expression profile of microRNAs and mRNAs in human placentas from pregnancies complicated by preeclampsia and preterm labor.

Authors:  Kathleen Mayor-Lynn; Tannaz Toloubeydokhti; Amelia C Cruz; Nasser Chegini
Journal:  Reprod Sci       Date:  2010-11-15       Impact factor: 3.060

2.  Protein kinase Cα suppresses the expression of STC1 in MDA-MB-231 breast cancer cells.

Authors:  Louise Cornmark; Gry Kalstad Lønne; Annika Jögi; Christer Larsson
Journal:  Tumour Biol       Date:  2011-07-01

Review 3.  Mammalian stanniocalcin-1 activates mitochondrial antioxidant pathways: new paradigms for regulation of macrophages and endothelium.

Authors:  David Sheikh-Hamad
Journal:  Am J Physiol Renal Physiol       Date:  2009-08-05

4.  Stanniocalcin1 is a key mediator of amyloidogenic light chain induced cardiotoxicity.

Authors:  Jian Guan; Shikha Mishra; Jianru Shi; Eva Plovie; Yiling Qiu; Xin Cao; Davide Gianni; Bingbing Jiang; Federica Del Monte; Lawreen H Connors; David C Seldin; Francesca Lavatelli; Paola Rognoni; Giovanni Palladini; Giampaolo Merlini; Rodney H Falk; Marc J Semigran; G William Dec; Calum A Macrae; Ronglih Liao
Journal:  Basic Res Cardiol       Date:  2013-08-28       Impact factor: 17.165

5.  Stanniocalcin-1 regulates re-epithelialization in human keratinocytes.

Authors:  Bonnie H Y Yeung; Chris K C Wong
Journal:  PLoS One       Date:  2011-11-01       Impact factor: 3.240

6.  Stanniocalcin-1 Reduces Tumor Size in Human Hepatocellular Carcinoma.

Authors:  Bonnie H Y Yeung; Felix H Shek; Nikki P Lee; Chris K C Wong
Journal:  PLoS One       Date:  2015-10-15       Impact factor: 3.240

7.  Effects of STC1 overexpression on tumorigenicity and metabolism of hepatocellular carcinoma.

Authors:  Cherry Ct Leung; Chris Kc Wong
Journal:  Oncotarget       Date:  2017-12-21

8.  Stanniocalcin1 (STC1) Inhibits Cell Proliferation and Invasion of Cervical Cancer Cells.

Authors:  Fengjie Guo; Yalin Li; Jiajia Wang; Yandong Li; Yuehui Li; Guancheng Li
Journal:  PLoS One       Date:  2013-01-29       Impact factor: 3.240

9.  CAPG enhances breast cancer metastasis by competing with PRMT5 to modulate STC-1 transcription.

Authors:  Sheng Huang; Yayun Chi; Yi Qin; Ziliang Wang; Bingqiu Xiu; Yonghui Su; Rong Guo; Liang Guo; Hefen Sun; Chujia Zeng; Shuling Zhou; Xin Hu; Sheng Liu; Zhimin Shao; Zhaohui Wu; Wei Jin; Jiong Wu
Journal:  Theranostics       Date:  2018-04-03       Impact factor: 11.556

Review 10.  Expression, function and clinical application of stanniocalcin-1 in cancer.

Authors:  Fangyu Zhao; Gang Yang; Mengyu Feng; Zhe Cao; Yueze Liu; Jiangdong Qiu; Lei You; Lianfang Zheng; Taiping Zhang; Yupei Zhao
Journal:  J Cell Mol Med       Date:  2020-05-29       Impact factor: 5.310

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.